Intravascular ultrasonography: Using imaging end points in coronary atherosclerosis trials

Paul Schoenhagen, MD
Department of Radiology, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Steven E. Nissen, MD
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Paul Schoenhagen, MD, Department of Radiology, Hb6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail schoenp1@ccf.org

The authors have indicated that they have received research support from the Pfizer, Merck, AstraZeneca, Sankyo, and Takeda corporations.

Paul Schoenhagen, MD
Department of Radiology, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Steven E. Nissen, MD
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Paul Schoenhagen, MD, Department of Radiology, Hb6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail schoenp1@ccf.org

The authors have indicated that they have received research support from the Pfizer, Merck, AstraZeneca, Sankyo, and Takeda corporations.

Paul Schoenhagen, MD
Department of Radiology, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Steven E. Nissen, MD
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation

Address: Paul Schoenhagen, MD, Department of Radiology, Hb6, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail schoenp1@ccf.org

The authors have indicated that they have received research support from the Pfizer, Merck, AstraZeneca, Sankyo, and Takeda corporations.